USHA ALAGESAN: Open Payments
NPI 1871928572 · FLEMINGTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,160 in 67 payments from 17 companies in 2025. Trend: 2023 $675 · 2024 $1,107 · 2025 $1,160
Food & beverage: $1,160
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $206 |
| Phathom Pharmaceuticals, Inc. | 13 | $149 |
| Janssen Biotech, Inc. | 6 | $117 |
| Braintree Laboratories, Inc. | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Ardelyx, Inc. | 4 | $75 |
| PFIZER INC. | 4 | $60 |
| Lilly USA, LLC | 3 | $58 |
| ABBVIE INC. | 3 | $57 |
| Madrigal Pharmaceuticals | 3 | $55 |
Products named: XIFAXAN, VOQUEZNA, TREMFYA, SUFLAVE, ENTYVIO, IBSRELA, OMVOH, RINVOQ.
Industry payments across NJ — which companies pay providers there.
